Drugs & Targets Mythic Therapeutics receives FDA Fast Track designation for MYTX-011 in NSCLC with cMET overexpression September 29, 2023Vol.49 No.36
Drugs & Targets FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer September 22, 2023Vol.49 No.35
Funding Opportunities FDA opens application for Orphan Products Clinical Trials Grant Program September 15, 2023Vol.49 No.34
Drugs & Targets FDA grants accelerated approval to Elrexfio for r/r multiple myeloma September 08, 2023Vol.49 No.33
Drugs & Targets FDA places partial clinical hold for magrolimab studies in AML September 08, 2023Vol.49 No.33
Drugs & Targets FDA expands Reblozyl’s indication to first-line treatment of anemia in lower-risk myelodysplastic syndromes September 08, 2023Vol.49 No.33
Drugs & Targets FDA clears AION’s continuous temperature monitoring device and software platform September 08, 2023Vol.49 No.33
Drugs & TargetsFree FDA grants accelerated approval to Talvey for R/R multiple myeloma August 11, 2023Vol.49 No.32
